Sugi Predict

Sugi Predict / Compounds / SCHEMBL28049

SCHEMBL28049

SCHEMBL28049

CO[C]C1c2ccccc2-c2ccccc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GPR3 P46089 2/20 0.41
▸ POLB P06746 3/20 0.39
▸ HTR2A P28223 1/20 0.37
▸ ACHE P22303 2/20 0.34
▸ CHRM2 P08172 1/20 0.34
▸ HTR1A P08908 1/20 0.34
▸ ADRA2A P08913 1/20 0.34
▸ CHRM1 P11229 1/20 0.34
▸ DRD1 P21728 1/20 0.34
▸ SLC6A2 P23975 1/20 0.34
▸ SLC6A4 P31645 1/20 0.34
▸ ADRA1A P35348 1/20 0.34
▸ OPRM1 P35372 1/20 0.34
▸ DRD3 P35462 1/20 0.34
▸ SLC6A3 Q01959 1/20 0.34
▸ HRH3 Q9Y5N1 1/20 0.34
▸ GAA P10253 1/20 0.34
▸ KMT2A Q03164 3/20 0.33
▸ MEN1 O00255 2/20 0.33
▸ SLC22A2 O15244 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19489752 0.69 POLB (0.54) GPR3POLBHTR2AACHECHRM2
SCHEMBL10518378 0.69 GPR3 (0.46) GPR3POLBHTR2AACHECHRM2
SCHEMBL68229 0.69 GPR3 (0.41) GPR3POLBHTR2AKMT2AMEN1
SCHEMBL6648437 0.69 PIM1 (0.56) GPR3POLBHTR2AACHECHRM2
SCHEMBL2747277 0.69 GPR3 (0.41) GPR3POLBHTR2AACHECHRM2
SCHEMBL5084440 0.69 GPR3 (0.41) GPR3POLBHTR2AACHECHRM2
SCHEMBL2189907 0.69 GPR3 (0.41) GPR3POLBHTR2AACHECHRM2
SCHEMBL40599 0.64 GPR3 (0.52) GPR3POLBHTR2AACHECHRM2
SCHEMBL29641604 0.64 GPR3 (0.52) GPR3POLBHTR2AACHECHRM2
SCHEMBL1906187 0.64 GPR3 (0.41) GPR3POLBHTR2AACHECHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3464285-A1 PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE Samumed, LLC (US) 2019-04-10 — — EP claimed
WO-2017210407-A1 PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE SAMUMED, LLC (US) 2017-12-07 — — WO claimed
CN-102260349-A Anti-amyloid beta protein (A beta) 31-35 antibody for treating and preventing Alzheimer's disease (AD), and preparation method thereof — 2011-11-30 — — CN claimed
WO-2008114976-A1 SPINORPHIN DERIVATIVES AS POTENT AND SELECTIVE HUMAN P2X3 RECEPTOR ANTAGONIST ANYGEN CO., LTD. (KR) 2008-09-25 — — WO claimed
WO-2000030646-A1 HETEROCYCLIC COMPOUNDS REGULATING CLOTTING NOVO NORDISK A/S (DK) 2000-06-02 — — WO claimed
US-11434192-B2 Process and intermediates NOVARTIS AG (CH) 2022-09-06 — — US disclosed
US-11235001-B2 RUNX inhibitor KYOTO UNIVERSITY (JP) 2022-02-01 — — US disclosed
US-20210246122-A1 Triazine Compounds and Uses Thereof Aduro Biotech, Inc. (US) 2021-08-12 — — US disclosed
EP-3558930-B1 NEW PROCESS FOR EARLY SACUBITRIL INTERMEDIATES NOVARTIS AG (CH) 2021-05-26 — — EP disclosed
EP-3810600-A1 TRIAZINE COMPOUNDS AND USES THEREOF Aduro BioTech, Inc. (US) 2021-04-28 — — EP disclosed
EP-3500549-B1 NEW PROCESSES AND INTERMEDIATES FOR NEP INHIBITOR SYNTHESIS NOVARTIS AG (CH) 2020-12-16 — — EP disclosed
US-10851059-B2 Processes and intermediates for NEP inhibitor synthesis NOVARTIS AG (CH) 2020-12-01 — — US disclosed
EP-0226217-B1 Peptides with sulfate ester group FISONS CORP (US) 1994-01-26 — — EP disclosed
WO-1994001451-A2 METHOD FOR MODIFICATION OF RECOMBINANT POLYPEPTIDES BIONEBRASKA, INC. (US) 1994-01-20 — — WO disclosed
EP-0532746-A4 ASSAY FOR NON-A NON-B HEPATITIS — 1993-07-21 — — EP disclosed
EP-0532746-A1 ASSAY FOR NON-A NON-B HEPATITIS. BAXTER DIAGNOSTICS INC (US) 1993-03-24 — — EP disclosed
WO-1992017612-A1 ASSAY FOR NON-A NON-B HEPATITIS BAXTER DIAGNOSTICS INC. (US) 1992-10-15 — — WO disclosed
EP-0470256-A1 PEPTIDE DERIVATIVES AND PRODUCTION THEREOF Takeda Chemical Industries, Ltd. (JP) 1992-02-12 — — EP disclosed
WO-1991013089-A1 PEPTIDE DERIVATIVES AND PRODUCTION THEREOF TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1991-09-05 — — WO disclosed
EP-0298474-A2 Novel calcitonin derivative and salt thereof MITSUBISHI PETROCHEMICAL CO., LTD. (JP) 1989-01-11 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210246122-A1 Triazine Compounds and Uses Thereof IL5, IL15, TLR5 GPR3 2298/4885POLB 4466/4885HTR2A 317/4885
US-11235001-B2 RUNX inhibitor RUNX1, MLX, CBX2 GPR3 1634/4885POLB 171/4885HTR2A 1862/4885
US-10851059-B2 Processes and intermediates for NEP inhibitor synthesis MME, ACE, DNPEP GPR3 3212/4885POLB 1519/4885HTR2A 1898/4885
US-11434192-B2 Process and intermediates MME, ACE, DNPEP GPR3 3296/4885POLB 1451/4885HTR2A 1701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.